UBS AM’s Orexigen Therapeutics, Inc. OREX Stock Holding History

UBS AM’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-6,520	Closed	-$37K	–	2687
2016 Q1	$37K	Sell	6,520 -30,973	-83%	-$402K	﹤0.01%	2621
2015 Q4	$645K	Sell	37,493 -83,392	-69%	-$1.99M	﹤0.01%	1911
2015 Q3	$2.55M	Sell	120,885 -48,270	-29%	-$1.65M	﹤0.01%	1314
2015 Q2	$8.37M	Buy	169,155 +1,250	+0.7%	+$74.7K	0.01%	937
2015 Q1	$13.1M	Buy	167,905 +1,800	+1%	+$112K	0.01%	807
2014 Q4	$10.1M	Hold	166,105	–	–	0.01%	864
2014 Q3	$7.08M	Sell	166,105 -16,050	-9%	-$862K	0.01%	953
2014 Q2	$11.3M	Buy	182,155 +3,500	+2%	+$204K	0.01%	813
2014 Q1	$11.6M	Buy	178,655 +37,900	+27%	+$2.56M	0.01%	801
2013 Q4	$7.92M	Sell	140,755 -16,555	-11%	-$930K	0.01%	889
2013 Q3	$9.66M	Buy	157,310 +48,480	+45%	+$3.28M	0.01%	812
2013 Q2	$6.37M	Buy	+108,830	New	+$6.7M	0.01%	896

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

TAM

Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS AM's OREX Position: Q2 2016 in Review

UBS AM sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2016, closing a stake of 6,520 shares — an estimated $37K sold.

UBS AM first reported a position in OREX in Q2 2013 and held it in 12 quarters. The position peaked at $13.1M in Q1 2015. 73 funds tracked by Wall St. Rank hold OREX as of Q2 2016.

UBS AM reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
UBS AM sold 6,520 Orexigen Therapeutics, Inc. shares in Q2 2016, an estimated $37K.
UBS AM first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 12 quarters.
UBS AM's Orexigen Therapeutics, Inc. position peaked at $13.1M in Q1 2015.
73 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2016.

Based on UBS AM's 13F filing for Q2 2016, filed 9 Aug 2016.